⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for adult acute myeloid leukemia with minimal differentiation

Every month we try and update this database with for adult acute myeloid leukemia with minimal differentiation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in RemissionNCT00093470
Acute Myeloid L...
Adult Acute Meg...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Alkylating Agen...
Myelodysplastic...
Recurrent Adult...
Clinical Observ...
Tipifarnib
18 Years - National Cancer Institute (NCI)
Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative DisordersNCT00588991
Adult Acute Meg...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Chronic Myeloid...
Chronic Myelomo...
de Novo Myelody...
Essential Throm...
Hematopoietic a...
Myelodysplastic...
Polycythemia Ve...
Recurrent Adult...
Recurrent Adult...
Secondary Myelo...
Carboplatin
Laboratory Biom...
Topotecan Hydro...
Veliparib
18 Years - National Cancer Institute (NCI)
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous LeukemiaNCT00217646
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Pro...
Adult Erythrole...
Adult Pure Eryt...
Alkylating Agen...
Blastic Phase
de Novo Myelody...
Previously Trea...
Recurrent Adult...
Recurrent Adult...
Secondary Acute...
Secondary Myelo...
Sorafenib Tosyl...
18 Years - National Cancer Institute (NCI)
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid LeukemiaNCT01168219
Acute Myeloid L...
Adult Acute Meg...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Alkylating Agen...
de Novo Myelody...
Myelodysplastic...
Myelodysplastic...
Recurrent Adult...
Secondary Myelo...
Allogeneic Hema...
Anti-Thymocyte ...
Azacitidine
Busulfan
Fludarabine Pho...
Laboratory Biom...
Methotrexate
Pharmacological...
Tacrolimus
18 Years - 74 YearsNational Cancer Institute (NCI)
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous LeukemiaNCT00217646
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Pro...
Adult Erythrole...
Adult Pure Eryt...
Alkylating Agen...
Blastic Phase
de Novo Myelody...
Previously Trea...
Recurrent Adult...
Recurrent Adult...
Secondary Acute...
Secondary Myelo...
Sorafenib Tosyl...
18 Years - National Cancer Institute (NCI)
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast PhaseNCT00383474
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Blastic Phase
Recurrent Adult...
Recurrent Adult...
Recurrent Disea...
Untreated Adult...
Untreated Adult...
Bortezomib
Laboratory Biom...
Tipifarnib
18 Years - National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in RemissionNCT00093470
Acute Myeloid L...
Adult Acute Meg...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Alkylating Agen...
Myelodysplastic...
Recurrent Adult...
Clinical Observ...
Tipifarnib
18 Years - National Cancer Institute (NCI)
Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid LeukemiaNCT01870596
Adult Acute Meg...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Alkylating Agen...
Recurrent Adult...
Cytarabine
CHK1 Inhibitor ...
Laboratory Biom...
18 Years - 75 YearsNational Cancer Institute (NCI)
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous LeukemiaNCT00217646
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Pro...
Adult Erythrole...
Adult Pure Eryt...
Alkylating Agen...
Blastic Phase
de Novo Myelody...
Previously Trea...
Recurrent Adult...
Recurrent Adult...
Secondary Acute...
Secondary Myelo...
Sorafenib Tosyl...
18 Years - National Cancer Institute (NCI)
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous LeukemiaNCT00217646
Adult Acute Bas...
Adult Acute Eos...
Adult Acute Meg...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Pro...
Adult Erythrole...
Adult Pure Eryt...
Alkylating Agen...
Blastic Phase
de Novo Myelody...
Previously Trea...
Recurrent Adult...
Recurrent Adult...
Secondary Acute...
Secondary Myelo...
Sorafenib Tosyl...
18 Years - National Cancer Institute (NCI)
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid LeukemiaNCT01307579
Acute Myeloid L...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Alkylating Agen...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Childhood Acute...
Fungal Infectio...
Myeloid Neoplas...
Neutropenia
Recurrent Adult...
Recurrent Child...
Secondary Acute...
Untreated Adult...
Untreated Child...
Caspofungin Ace...
Fluconazole
Laboratory Biom...
3 Months - 30 YearsChildren's Oncology Group
Tipifarnib in Treating Older Patients With Acute Myeloid LeukemiaNCT01361464
Adult Acute Meg...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Alkylating Agen...
Secondary Acute...
Untreated Adult...
Tipifarnib
Laboratory Biom...
65 Years - National Cancer Institute (NCI)
Tipifarnib in Treating Older Patients With Acute Myeloid LeukemiaNCT01361464
Adult Acute Meg...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Alkylating Agen...
Secondary Acute...
Untreated Adult...
Tipifarnib
Laboratory Biom...
65 Years - National Cancer Institute (NCI)
Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid LeukemiaNCT01870596
Adult Acute Meg...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Alkylating Agen...
Recurrent Adult...
Cytarabine
CHK1 Inhibitor ...
Laboratory Biom...
18 Years - 75 YearsNational Cancer Institute (NCI)
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: